Alumis Inc. (ALMS)
| Market Cap | 3.17B +624.9% |
| Revenue (ttm) | 24.05M |
| Net Income | -243.33M |
| EPS | -2.86 |
| Shares Out | 127.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,248,339 |
| Open | 26.04 |
| Previous Close | 25.99 |
| Day's Range | 24.83 - 26.19 |
| 52-Week Range | 2.76 - 30.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.30 (+45.61%) |
| Earnings Date | May 13, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price target is $36.3, which is an increase of 45.61% from the latest price.
News
Alumis Transcript: Study update
Envudeucitinib’s phase III ONWARD trials showed robust skin clearance, rapid itch reduction, and strong quality-of-life improvements in moderate to severe plaque psoriasis, with a favorable safety profile through 24 weeks. Its efficacy, especially in itch relief, positions it as a leading oral option, with further studies planned.
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psori...
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envud...
Alumis Transcript: Leerink Global Healthcare Conference 2026
Envudeucitinib showed top-tier efficacy and rapid onset in phase III psoriasis trials, with long-term data and NDA filing expected in the second half of the year. The company is expanding its TYK2 franchise into lupus and other indications, with a focus on strategic partnerships and a once-daily formulation in development.
Alumis to Present at the Leerink Partners Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediat...
Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Positive Phase 3 data for envudeucitinib in psoriasis showed strong efficacy and safety, with NDA submission planned for the second half of the year. SLE pivotal trial data is expected in Q3, and the company is evaluating broader TYK2 franchise opportunities and potential partnerships.
Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Phase III data for envudeucitinib in psoriasis showed strong efficacy and safety, with NDA filing planned for the second half of the year. The company is preparing for commercial launch and expanding its pipeline into SLE, MS, and other autoimmune indications, supported by a strong cash position.
Alumis to Participate in Upcoming February Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediate...
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Alumis Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Alumis Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars
Alumis Inc. (NASDAQ: ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro.
Alumis Transcript: Study Result
Envudeucitinib achieved highly significant efficacy and safety in phase III psoriasis trials, with rapid and deep skin clearance, strong patient-reported outcomes, and a favorable safety profile. The results support its potential as a leading oral therapy, with broader applications in immune-mediated diseases and an NDA filing planned for late 2026.
Alumis skin disease drug meets main goal of two late-stage trials
Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease.
Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90...
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with im...
Alumis Transcript: Stifel 2025 Healthcare Conference
Multiple late-stage readouts for oral TYK2 inhibitor Envudeucitinib in psoriasis and lupus are expected in 2026, with strong efficacy and safety data supporting its potential. Strategic plans include partnering the lead asset and advancing additional pipeline candidates, supported by a cash runway into 2027.
Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Envutuzitinib is advancing with key phase III psoriasis and phase IIb lupus data expected in 2024, supported by strong safety and efficacy profiles. The company maintains a robust pipeline and financial position, with over $480 million in cash and operational runway into 2027.
Alumis to Participate in Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediate...
Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum
Alumis is advancing a robust immunology pipeline led by ESK-001, a next-gen TYK2 inhibitor for psoriasis and lupus, with key readouts in 2024. The company is well-funded through 2027, preparing for potential independent commercialization, and exploring additional indications and assets.
Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Lead TIK2 inhibitor Envu is advancing in phase 3 for psoriasis and phase 2 for lupus, with key data readouts expected in early 2025 and late summer 2025, respectively. The company maintains a strong financial position, is expanding its pipeline, and is preparing for global commercialization with a focus on high-efficacy oral therapies and strategic flexibility.
Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The company is advancing precision immunology with lead TYK2 inhibitor programs in psoriasis and lupus, aiming for key readouts in 2024. Differentiation is based on sustained target inhibition and a strong safety profile, with a robust financial position supporting strategic flexibility.
Alumis Transcript: Cantor Global Healthcare Conference 2025
Three clinical assets are advancing, with phase III psoriasis and pivotal lupus trial readouts expected in 2024. The lead TYK2 inhibitor shows strong efficacy and safety, aiming for a 2026 filing. Market strategy focuses on oral preference and global partnerships, with $486M in cash runway into 2027.